FindTrial
Sign In

Methotrexate Placebo

DRUG5 trials

Sponsors

AbbVie (prior sponsor, Abbott), Bristol-Myers Squibb, CSL Behring, Assistance Publique Hopitaux De Marseille

Conditions

Early Rheumatoid ArthritisPsoriasisRheumatoid Arthritis

Phase 2

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
CompletedNCT01373151
CSL BehringRheumatoid Arthritis
Start: 2011-06-30End: 2015-06-30Updated: 2021-12-06

Phase 3

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis
CompletedNCT00195663
AbbVie (prior sponsor, Abbott)Early Rheumatoid Arthritis
Start: 2000-12-31End: 2012-04-30Updated: 2013-07-12
Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis
CompletedNCT01142726
Bristol-Myers SquibbRheumatoid Arthritis
Start: 2010-12-31End: 2014-10-31Updated: 2016-01-14
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
CompletedNCT02504268
Bristol-Myers SquibbRheumatoid Arthritis
Start: 2015-09-03End: 2020-03-19Updated: 2021-06-28

Phase 4

Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis
TerminatedNCT02829424
Assistance Publique Hopitaux De MarseillePsoriasis
Start: 2017-01-23End: 2024-02-10Updated: 2025-11-20

Related Papers

Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis.
2026-02-24
Association Between Abatacept Exposure Levels and Infection Occurrence in Patients With Rheumatoid Arthritis: Post Hoc Analysis of the AVERT-2 Study
The Journal of Rheumatology2025-01-151 citations
The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study.
2023-04-222 citations
Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis.
2023-03-038 citations
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis
RMD Open2022-12-013 citations
Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept.
2022-02-1611 citations
Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials
Lara D. Veeken2019-12-0210 citations
Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials.
2019-11-106 citations
Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled Trial.
2019-07-055 citations
Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study
RMD Open2019-02-019 citations
On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis
Rheumatology International2018-10-205 citations
Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate.
2018-08-0319 citations
Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis
RMD Open2018-06-016 citations
Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
RMD Open2017-09-0110 citations
Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
Annals of the Rheumatic Diseases2016-06-24107 citations
Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis.
2016-02-1018 citations
Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis
Arthritis Research & Therapy2015-05-2017 citations
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.
2014-11-03182 citations
Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?
2014-08-1930 citations
Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
2013-11-1545 citations

1 more papers not shown